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CTVprostate+3mm D90 was in accordance with institutional 
constraints (95% of prescribed dose) in 74 of 81 procedures. 
Insufficient coverage was caused by suboptimal needle 
implant (5 procedures) and catheter migration (2 
procedures). CTVprostate+3mm D90 was significantly improved 
over time, and tended to be better at the second HDR BT. 
Urethral dose D0.1cc constraints was fulfilled (<=10 Gy) in 65 
of 81 procedures. Rectal dose D2cc constraint was fulfilled 
(<6.4 Gy) in 79 of 81 procedures. Increased CTVprostate+3mm D90 
was not related with increased urethral or rectal dose. 
Conclusions: After introduction of MRI guided HDR BT, 
implant time and total procedure time was reduced to ~2.5 
hours and ~5 hours, respectively. Post implant MRI prolonged 
the HDR BT procedure by an estimated median of 66 min. 
Dose to CTVprostate+3mm mostly fulfilled institutional constraints 
and was improved over time, but not at the expense of an 
increased urethral or rectal dose.  
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Purpose/Objective: The aim of the present prospective study 
is to analyze short and intermediate-term outcomes and 
toxicity after salvage brachytherapy (BT) with I-125 for local 
failure after BT or external beam radiotherapy (EBRT) for 
prostate cancer. 
Materials and Methods: From January 2010 and September 
2014, 24 patients with PSA relapse (Phoenix definition for 
those with previous androgen deprivation (AD) and ASTRO 
definition for the rest), and histological confirmation with 
template-guided biopsy, underwent salvage BT with I-125 at 
least 2 years after the initial treatment (15 BT and 9 EBRT). 
Magnetic resonance imaging (MRI) and/or PET-CT as study of 
distant disease were realized in every case. At relapse, 
average age was 71 years (58-82), median Gleason was 7 and 
PSA pre-salvage BT 5.65 ng/ml (2.81-11.7). Two patients 
were treated with androgen deprivation therapy (ADT) 
previously salvage BT. The median dose to 90% of prostate 
volume was 129.1 Gy (84.18-151.47) with a median seed 
activity of 0.506 mCi (0.319-0.518). Constraint median doses 
for urethra and rectum were 162 Gy and 120 Gy, 
respectively. Every case required post-planning with post 
implant-CT. Post implant-MRI was realized in-patient without 
history of brachytherapy with iodine-125 radiation seeds. 
Toxicities were graded using CTCv4.0. 
Results: With a median follow up of 39 months (2-55): 19 
(79%) patients are free from biochemical failure, 3 patients 
have developed PSA relapse with distant failure evidence, 2 
patients presented PSA relapse within the first 6-12 months 
after salvage brachytherapy. The toxicities found 
corresponding to: one case grade 3 (TURP after acute urine 
retention) and two cases grade 2 (acute rectal mucositis and 
acute cystitis in the same patient). 
Conclusions: Despite of the short follow-up in some patients, 
BT seems to be a safe and effective treatment option for 
salvage treatment, but careful patient selection is essential 
to improve outcomes. 
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Purpose/Objective: Stereotactic Ablative Radiotherapy 
(SABR) is increasing in popularity in several tumour sites 
including prostate cancer. A pilot study of low to 
intermediate risk Prostate cancer patients treated using 
Volumetric Arc Therapy (VMAT) and Flattening Filter Free 
(FFF) beams is ongoing at our institution. Initial toxicity data 
are presented in this report. 
Materials and Methods: Key inclusion criteria in the study 
was patients with low to intermediate risk, localised Prostate 
cancer. Staging was performed using MRI in all patients and a 
bone scan in selected cases. Planning CT and MRI were 
obtained on the same day, with bladder and bowel 
preparation. MRI and CT planning scans were fused and, 
following this, prostate, seminal vesicles and organs at risk 
were outlined by a consultant Clinical Oncologist. VMAT plans 
were produced utilising 10X FFF beams RapidArc 10.028 and 
AAA 10.0.2.28 algorithms. Patients were treated on a Varian 
TrueBeam STx Linear Accelerator at a dose of 35Gy/5 
fractions delivered on alternate days. Cone Beam CT was 
used before each treatment to verify treatment position 
using fiducial marker (gold seed) and soft tissue matching. 
Toxicity was assessed using RTOG toxicity grading prior to 
each fraction of radiotherapy and then at week 4, 10, 18 and 
6 months.  
Results: To date, 22 patients have been enrolled into the 
study. Median age is 70 years, range 52-78yrs. All patients 
have clinical and radiological stage T1-2 disease. Median iPSA 
was 10.65, range 4-29.2 µg/l. 
We have toxicity data on 17 patients who have so far 
completed at least 10 weeks follow up, assessed using RTOG 
acute toxicity scoring. 
 Genitourinary toxicity;  
o 9 patients (53%) had grade 1 symptoms at 
baseline  
o 6 patients (35%) developed grade 2 
toxicity; resolved to grade 1 by week 18 
in all patients (1 not yet reached week 18 
follow-up)  
 
 Gastrointestinal toxicity  
o 2 patients (12%) developed grade 2 
toxicity; both resolved to grade 1, 1 
patient by week 18 and the second 
patient by week 24.  
 
No patient experienced any Grade 3 or 4 toxicity. 
Conclusions: These preliminary data show that treating low 
to intermediate risk prostate cancer patients with SABR using 
VMAT and FFF is safe and deliverable in a busy Tertiary Care 
referral centre with mild, acute GI and GU toxicity. Long 
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term toxicity and efficacy data are clearly crucial and will be 
reported in due course. 
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Purpose/Objective: To evaluate the feasibility and toxicity 
of hypofractionated stereotactic body radiation therapy 
(SBRT) with volumetric modulated arc therapy (VMAT) and 
flattening filter-free (FFF) beams. 
Materials and Methods: A prospective designated phase I-II 
study was approved by our institutional review and ethics 
board (started in April 2013). Inclusion criteria were 
histologically proven prostate adenocarcinoma, Gleason Score 
6–7, clinical stage T1b–T2b, prostate-specific antigen (PSA) ≤ 
20 ng/mL, prostate volume ≤ 60 cc, no previous surgery, no 
malignant tumours in the previous 5 years, IPSS 0–7 Neo-
adjuvant/concomitant hormonal-therapy was prescribed 
according to risk classification. Image Guided RT with Cone 
Beam CT (with or without fiducial markers) is mandatory. 
Urinary catheter was needed to plan and deliver radiation in 
order to maintain bladder volume stable during treatment. 
SBRT was delivered at a prescribed planning target volume 
(PTV) dose of 35 Gy in five fractions in 5 alternative days 
using the TrueBeam with RapidArc VMAT, with 6 MV FFF 
photons. CTCAE v3.0 morbidity scores were used to assess 
toxicities. 
Results: A total of 11 patients have been recruited to date. 
Mean age of the patients was 71.2 years (range: 64–76 yr). 
Pathology centralized Gleason score was 6 in 6 patients and 7 
(3+4) in another five patients. Mean PSA was 9 ng/mL (range: 
0.03–17 ng/mL). According to D'Amico risk classification, 6/11 
patients were low-risk and 5/11 were intermediate risk. Mean 
prostate volume was 38.3 cc. All patients completed the 
treatment as programmed in 2 weeks and tolerated the 
treatment well. One haematuria related to renal colic and 
hypertensive crisis were observed in two different patients at 
the first session. Evaluating patients in a time period ranging 
from 3 to 18 months, no toxicity greater than grade 2 was 
observed. . Acute Toxicities were as follow: Rectum G0: 2/11 
cases (18.2%); G1: 5/11 (45.6%); G2: 4/11 (36.4%). Genito-
urinary: G1: 8/11 (72,3%); G2: 3/11 (27,3%). At 3 months 
follow-up toxicities were as follow: Rectum G0: 5/11 cases 
(45.6%); G1: 6/11 (54,5 %); G2: 1/11 (9.1%). Genito-urinary: 
G0: 4/11 (36.4%), G1: 6/11 (54.5 %); G2: 1/11 (9.1%).Test 
between average total IPSS at pre-entry when compared with 
1-month and 3-month evaluations showed a non-significant 
increase in mean value from 4 to 6. Biochemical response 
was seen at 3 month of follow-up with mean value of 2.1 
ng/ml (range from 0.03 to 5.89). 
Conclusions: Early findings indicate that SBRT with VMAT and 
FFF beams for low–intermediate-risk prostate cancer 
delivered in five fractions is feasible and well tolerated in 
selected patients. Long-term follow-up is needed for 
assessment of late toxicity and outcomes. 
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Purpose/Objective: Anterior rectal wall (ARW) receives 
inevitable high radiation dose in prostate cancer 
radiotherapy. The rectum-protective effect of endorectal 
ballooning (ERB) was assessed in terms of separate anatomic 
categorization focusing ARW and its dose distribution.  
Materials and Methods: Between Aug 2012 and Mar 2014, 
thirty one patients received curative tomotherapy for 
prostate cancer treatment. All treatment sessions were 
performed by intensity-modulated simultaneous integrated 
boost method to each target volume with customized 60 mL 
air balloon inserted into the rectum. The prescription dose 
was 70.0 Gy, 60.2 Gy, and 50.4 Gy to each planning target 
volume (PTV) for prostate gland (PG), seminal vesicles, and 
elective pelvic lymph node area with 28 fractionations, 
respectively. The ARW and posterior rectal wall (PRW) were 
contoured separately with 5 mm-thickness through the ERB-
inflated rectum area. In thirteen patients (49.1%, Group 1), 
PRW dose was restricted to maximum 40 Gy without ARW 
dose fixing. The other 18 patients (58.1%, Group 2) were 
treated by conventional dose constraint without additional 
dose condition to PRW area.  
Results: All patients completed their scheduled radiotherapy 
courses. The PG PTV dose distribution did not differ between 
the two groups (p = 0.694). The median PG PTV volume was 
46.5 mL (range, 15.9 - 127.2 mL), and its mean dose, D1%, V95% 
was 70.8 ± 0.65 Gy, 72.1 Gy, 69.8%, respectively. The 
overlapped volume between PG PTV and ARW was 13.4 mL. 
The mean dose and conformity index (V95%/VPG PTV) did not 
show significant difference between the two groups 
(p=0.405). The average dose, D1%, D50%, D70%, V20Gy, and V40Gy 
for ARW were not significantly different between the two 
groups. However, V60Gy had a tendency to be higher in Group 
1 (p=0.087). Acute rectal and urinary toxicities occurred in 4 
patients (12.9%) and 23 patients (74.2%), respectively, 
without Grade 3 or higher toxicity in both groups. No 
significant difference in rectal (p>0.999) and urinary 
(p=0.592) toxicity was showed between the two groups. 
Conclusions: Proper dose constraint to PRW showed tolerable 
acute toxicity profile without compromising PG PTV 
conformity despite the risk of high dose distribution to ARW 
area. However, radiobiological analysis may be required 
together with dose-volume approach in this relative 
conservative dose constraint condition. 
   
EP-1260   
Risk factors for acute toxicity in prostate cancer patients 
receiving hypofractionated IMRT 
F. Matrone1, G. Montesi1, S. Saldi1, R. Bellavita2, A. 
Frattegiani2, M. Lupattelli2, C. Zucchetti3, S. Cusco2, V. Bini4, 
C. Aristei5 
1University of Perugia, Radiation Oncology Section, Perugia, 
Italy  
